TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• 2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments

  80% confidence

• Almost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature

  80% confidence

• TransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue

  80% confidence

• Company is not seeing competitive dynamics impacting ability to execute in 2026 and beyond

  80% confidence

• OUS transplant revenue grew approximately 33% sequentially to $5 million

  80% confidence

• TransMedics was prepared and expected ENHANCE Part B trial challenges, and will execute Part B hoping for significant success

  80% confidence

• Total revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025

  80% confidence

• Company is laser-focused on ensuring successful execution of initiatives throughout 2026

  80% confidence

• Almost 50% of incremental 2026 investment is driven by three transitory elements

  80% confidence

• Total revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025

  80% confidence

• Gross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits

  80% confidence

• Total revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025

  80% confidence

• Most lung centers were waiting to see FDA approval before launching into DENOVO program

  80% confidence

• TransMedics is laser-focused on ensuring successful execution of these initiatives throughout 2026

  80% confidence

• TransMedics has huge opportunities ahead but also a few challenges and moving dynamics, with guidance factoring in all factors to be realistic and enable execution

  80% confidence

• OCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024

  80% confidence

• Liver market share gains are pure TransMedics execution excellence, period, full stop

  80% confidence

• Almost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature

  80% confidence

• U.S. transplant revenue grew approximately 11% sequentially to $155 million

  80% confidence

• Liver market share gains represent pure TransMedics execution excellence

  80% confidence

• OCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024

  80% confidence

• Operating margin expanded from 8.5% in 2024 to 18% in 2025

  80% confidence

• Operating margin expanded from 8.5% in 2024 to 18% in 2025

  80% confidence

• TransMedics has huge opportunities ahead but also faces a few challenges and moving dynamics, which have been factored into guidance

  80% confidence

• By organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4

  80% confidence

• TransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue for fourth quarter while making substantial investments to fuel growth

  80% confidence

• Gross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits

  80% confidence

• Upcoming OCS Liver registry publication will show unequivocal statistical superiority in the most important outcomes after liver transplantation

  80% confidence

• Operating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments

  80% confidence

• What's coming is really the unequivocal drop-the-mic statistical superiority in the most important outcomes after liver transplantation

  80% confidence